Iloprost for Bone Marrow Oedema and Avascular Osteonecrosis
Author Information
Author(s): Marcus Jäger, Frank Peter Tillmann, Thomas S Thornhill, Marcus Mahmoudi, Dirk Blondin, Gerd Rüdiger Hetzel, Christoph Zilkens, Rüdiger Krauspe
Primary Institution: Heinrich-Heine University Hospital Duesseldorf
Hypothesis
The study aims to assess the efficacy of the prostacyclin analogue iloprost in treating bone marrow oedema (BME) and avascular osteonecrosis (AVN).
Conclusion
Iloprost improves pain and functional outcomes in patients with early stages of BME and AVN.
Supporting Evidence
- Pain levels significantly decreased from 5.26 to 1.63 after six months.
- Harris Hip Score improved from 52.6 to 79.9 points after six months.
- Knee Society Score increased from 112.8 to 186.4 points at six months.
- 65 of 117 affected bones were free of BME within six months of iloprost application.
- SF-36 health survey scores improved significantly during and after treatment.
Takeaway
Iloprost is a medicine that can help reduce pain and improve movement for people with certain bone problems.
Methodology
The study involved a prospective, MRI-controlled observational design with 50 patients treated with iloprost, evaluating pain and functional scores before and after treatment.
Potential Biases
Potential biases may arise from the observational nature of the study and the exclusion of certain patient groups.
Limitations
The study did not include patients with advanced AVN stages, and the long-term effects beyond six months were not assessed.
Participant Demographics
Mean age of participants was 45.2 years, with a sex ratio of 22 men to 28 women.
Statistical Information
P-Value
p<0.01 for significant results, p>0.05 for non-significant results.
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website